CTLA4 and alveolar soft part sarcoma: Meanwhile, 5/10 (50%) of the patients with ASPS responded to treatment in the MD Anderson single arm phase II trial of durvalumab and tremelimumab [21], potentially reflecting a higher degree of activity of combination anti-PD-L1/CTLA-4 therapy.